Krankheiten

A ChemBioChem commentary argues that P3, a peptide long considered harmless, can form aggregates and may affect Alzheimer’s disease. Its role in patients is unknown.

A POSEIDON analysis found elevated hsCRP in about half of U.S. heart failure participants, while targeted anti-inflammatory treatments remain uncertain.

A 36-person trial linked N-acetylcysteine treatment to brain imaging changes and self-reported symptom improvements in people with mild to moderate MS.

A phase III study found investigational 124I-evuzamitide PET detected early cardiac amyloidosis more often than bone scans; Bayer plans FDA submission.

Interest in claims that vapes are harmful is rising, but the trigger is unconfirmed and the supplied image could not be read.

Friends of BrainHealth awarded grants to seven research projects, including studies of dementia risk, early detection, resilience and caregiver well-being.

Bonn researchers directly converted human blood-cell precursors into neural stem cells, tracking a gradual reset of epigenetic age in the laboratory.

In the 410-person NOPARK trial, nicotinamide riboside did not improve early Parkinson’s outcomes and was linked to modestly worse scores over 52 weeks.

The FDA has approved remibrutinib for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, based on phase III trial results.

A survey study found wider use of catheter-prevention measures from 2005 to 2025, but nurse-initiated removal remains uneven across hospitals.